Published in TB and Outbreaks Week, May 20th, 2003
For this study, "eligible subjects had received macrolide-based therapy for least 12 months, were asymptomatic for MAC, had received HAART for at least 16 weeks, and had CD4+ T-cell counts >100 cells/microL. Forty-eight subjects were enrolled, with a median CD4+ T-cell count of 240 cells/microL at the time of discontinuation of MAC therapy," said J.A. Aberg of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.